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Pregnancy is a complex immunological state in which a bias towards T helper 2 (Th2) protects the fetus. Evidence suggests that
proinﬂammatory cytokines increase the risk of poor neonatal outcome, independently of the direct eﬀe c to fp r e t e r ml a b o u r .
The anti-inﬂammatory prostaglandin 15-deoxy-Δ12,14-Prostaglandin J2 (15dPGJ2) inhibits nuclear factor Kappa B (NF-κB) in
amniocytes and myocytes in vitro and is a ligand for the chemoattractant receptor-homologous molecule expressed on Th2 cells
(CRTH2) receptor. Here we examine the Th1:Th2 cytokine bias in pregnancy and whether 15dPGJ2 could be used to inhibit
the production of the proinﬂammatory cytokines through inhibition of NF-κB while simultaneously promoting Th2 interleukin
4 (IL-4) synthesis via CRTH2 in T helper cells. Peripheral blood mononuclear cells (PBMCs) from women at 28 weeks, term
pre-labour, term labour as well as non-pregnant female controls were cultured with 15dPGJ2 or vehicle control and stimulated
with phorbol myristyl acetate (PMA)/ionomycin. The percentage of CD4+ cells producing interferon gamma (IFN-γ) and tumor
necrosis factor alpha (TNF-α) in response to PMA/ionomycin was signiﬁcantly reduced in pregnancy. 15dPGJ2 reduced IFN-γ
and TNF-α production in stimulated T helper cells, but did not alter IL-4 production in CRTH2+ve cells. 15dPGJ2 also reduced
phospho-p65 in stimulated PBMCs. In summary, 15dPGJ2 suppresses the Th1 response of PBMCs during pregnancy and active
labour whilst maintaining the Th2 response suggesting a therapeutic beneﬁt in reducing neonatal morbidity in inﬂammation-
induced PTL.
1.Introduction
Preterm labour <34weeksoccursinabout4%ofpregnancies
[1]. In 80–85% of cases of spontaneous preterm labour
(PTL) <28 weeks, there is evidence of intrauterine infection
[2]. Despite increased awareness of the association between
inﬂammation and preterm labour [3], there have been no
major advances in the prevention of preterm labour which
have been shown to improve long-term neonatal outcomes.
During normal term labour, the uterus and cervix become
inﬁltrated with leukocytes and undergo changes in response
to local secretion of proinﬂammatory cytokines. A similar
pattern of biochemical events occur during PTL; however,
the triggers for this premature activation are still not fully
understood. Regardless,thepresenceofincreasedproinﬂam-
matory cytokines during pregnancy is clearly associated with
a poor prognosis for babies born preterm [4].
The immune system can generally be divided into
the innate and adaptive immune system. The former is
a nonspeciﬁc system providing immediate defence against
pathogens, while the latter is more targeted, characterised
by T and B lymphocytes. Although cross-talk between these
lymphocytes exist, B cells and their antibodies mainly give
rise to humoral immunity, whereas T cells primarily provide
cell mediated immunity [5]. T helper cells (CD4+)f o r m
a subset of T cells and can be further subdivided into T
helper 1 cells (Th1) and T helper 2 cells (Th2) depending
on their pattern of cytokine production. Th1 cells secrete2 Mediators of Inﬂammation
pro inﬂammatory cytokines such as interferon gamma (IFN-
γ) and tumor necrosis factor alpha (TNF-α), whereas the
Th2 cells secrete anti-inﬂammatory cytokines such as inter-
leukin 4 (IL-4), IL-10, and IL-13 [6]. A mutually exclusive
interaction exists between the Th1 interleukin, IFN-γ,a n d
the Th2 interleukin, IL-4. IL-4 is the dominant factor for
promoting growth and diﬀerentiation from the Th0 to the
Th2 subtype, and directly inhibits the development of the
Th1 cells [7]. IFN-γ indirectly promotes Th1 diﬀerentiation
by upregulating the IL-12 receptor whilst inhibiting the
growth of Th2 cells [8, 9].
Wegmann and colleagues ﬁrst developed the concept
that during pregnancy there is a shift from a T helper 1
(Th1) response to a T helper 2 (Th2) bias during pregnancy
thatfunctionallyinducesmaternaltoleranceandsuppression
[10]. Consistent with this notion, administration of the
Th1 interleukins IFN-γ [11] and IL-2 [12] leads to fetal
loss and preterm labour in the mouse. Similarly, CBA ×
DBA/2 mice that have placentas deﬁcient in IL-4 and IL-10
are prone to fetal resorption. Treatment of these mice via
intraperitoneal injection of IL-10 protects the fetuses from
resorption [13]. Several human studies have shown a Th2
bias in the ratio of circulating T helper cytokine proﬁle
in normal pregnancy; and an increase in the Th1 ratio in
cases of recurrent miscarriage [14] and in preeclampsia [15].
Peripheral blood lymphocytes taken from women in the
ﬁrst trimester show an increased production of IL-4 and
IL-10 and less IFN-γ compared to nonpregnant controls in
vitro [16]. There is in vivo evidence in pregnant women
of increased expression of IL-4 messenger ribonucleic acid
(mRNA) and lower expression of the IFN-γ mRNA [17].
Not all studies support the requirement of the shift from
Th1 to Th2 for successful pregnancy outcome [18, 19].
Despite showing a suppression of IFN-γ and an increase in
IL-10 during pregnancy compared to nonpregnant controls,
Bates et al. showed no diﬀerence in IFN-γ, IL-10, or IL-4
secretion in women who subsequently miscarried compared
with those who went on to complete their pregnancy [18].
However, contrary to this study, women with recurrent
miscarriage have been shown to have increased IFN-γ and
TNF-α levels compared with women that go on to have
successfulpregnancies[20].Whilethemechanismregulating
theTh1:Th2ratioisyettobefullyelucidatedtheimportance
of maternal immune tolerance during pregnancy is unques-
tionable. Several pregnancy-related proteins are known to
promote Th2 bias such as leukemia inhibitory factor [21],
progesterone, progesterone-induced blocking factor [22],
and estradiol [23]. Prostaglandin D2 (PGD2)p r o m o t e sI L - 4 ,
IL-13, IL-5, and IL-10 production in T helper 2 cells in vitro
via the second PGD2 receptor; chemoattractant receptor-
homologous molecule expressed on Th2 cells (CRTH2) [24].
PGD2 is produced by the placenta and may play a role in the
chemoattraction of Th2 cells via the CRTH2 receptor to the
maternal fetal interface to produce a localised Th2 bias [25].
15-deoxy-Δ12,14-Prostaglandin J2 (15dPGJ2), an endoge-
nous prostaglandin (PG), is a product of PGD2 v i aas e r i e s
of dehydration reactions [26]. As well as being a ligand for
Peroxisome proliferator-activated receptor gamma (PPARγ),
it is also an agonist of the CRTH2 receptor [27]. We have
previously demonstrated that this anti-inﬂammatory PG
inhibits nuclear factor Kappa B (NF-κB) in amniocytes and
myocytes in vitro [28] and delays infection induced preterm
labour and increases pup survival in the mouse via NF-κB
inhibition [29]. Moreover, recent work has shown that the
ﬁrsttrimesterofpregnancyisassociatedwiththesuppression
of available T cell NF-κBa n dr e d u c e dl e v e l so fI F N - γ
compared to nonpregnant controls [30, 31]. Collectively
these data suggest that the Th1:Th2 ratio is modulated
through the regulatory interplay of both Th1 suppression
and Th2 promotion.
In this study, we examined the expression of the dom-
inant Th1 interleukins IFN-γ and TNF-α, and the Th2
interleukin IL-4 in T helper cells obtained from nonpregnant
women, women in the early and late third trimester, and
duringlabour.WeexaminedtheeﬀectoftheCRTH2agonist,
15dPGJ2, on these interleukins and on NF-κBa c t i v a t i o na t
diﬀerent gestational time points to determine its potential
role in suppressing the Th1 response via NF-κB whilst
simultaneously promoting the Th2 response via CRTH2.
2.MaterialsandMethods
2.1. Subjects. Pregnant women at 28 weeks and term
(prelabour and in labour) and nonpregnant women of
child bearing age were included in the study in accordance
with ethical approval from the South East London Ethical
Committee Ref. 10/H0805/54. Exclusion criteria included
women with Asthma and HIV, women not of childbearing
age, and women with a fever. After obtaining informed
consent, 5mL of peripheral venous blood was collected
in sodium citrate tubes, and processed within 30mins of
collection. Unless otherwise stated, a minimum of 4 subjects
were included for each experimental sample group.
2.2. Isolation of Peripheral Blood Mononuclear Cells (PBMCs).
Blood was diluted 1:1 with phosphate-buﬀered saline
(PBS) and carefully layered onto Ficoll-Paque PLUS (GE
Healthcare, Uppsala, Sweden) before centrifuging at 400×g
for 40mins at room temperature. After centrifugation, the
halo containing PBMCs was carefully transferred into a
clean centrifuge tube and washed twice with 7mL of PBS.
After centrifugation (400×g for 10mins), the cell pellet was
resuspended in either PBS or RPMI 1640 (Invitrogen Life
Technologies, Grand Island, NY, USA) culture medium.
2.3. CRTH2 Expression Studies. The PBMC pellet was resus-
pended PBS, and cells were counted with a Neubauer
haemocytometer and then resuspended in staining buﬀer
(1% fetal calf serum; 0.09% sodium azide in PBS) to
obtain roughly 3.5 × 106 cells per sample. Preparations
were incubated in the dark for 1h at 37◦Cw i t h2 0 μL
of CRTH2-phycoerythrin (CRTH2-PE) (Beckman Coulter,
High Wycombe, UK) and 3μL of CD4-Allophycocyanin
(CD4-APC) (BD Pharminogen, Oxford, UK) or the relevant
isotypecontrols;RatImmunoglobulin(Ig)G2a-PE(Beckman
Coulter) and Mouse IgG1κ-APC (BD Pharminogen). After
incubation, the PBMC suspension was washed twice inMediators of Inﬂammation 3
1mL of PBS and then resuspended in PBS for analysis.
Flow cytometry settings were as follows: forward scatter E0
voltage, 1.00Amp gain Lin, and side scatter of 329 voltage,
1.00Amp gain Lin. A total of 50,000 cells were counted and
gating was on lymphocytes based on the forward and side
scatter.
2.4. Intracellular Cytokine Studies (IL-4, IFN-γ,a n dT N F -
α). For intracellular cytokine studies, cells were resuspended
in RPMI 1640 (Invitrogen) media supplemented with 10%
fetal calf serum, 2mM/L L-glutamine, 100U/mL penicillin,
and 100μg/mL of streptomycin (Sigma, St. Louis, MO, USA)
before being plated in 24-well plates and incubated for 18h
in 5% CO2/humidiﬁed air at 37◦C. Following this, 10μgo f
brefeldin A (Sigma) was added to each well to immobilize
the interleukins in the golgi apparatus. Cells were pretreated
with32μMo f1 5 d PG J 2 (Cayman Chemicals, Ann Arbor, MI,
USA) or dimethyl sulfoxide (DMSO) (Sigma) vehicle control
for2hinthecaseofIFN-γ andTNF-αexperiments or 1h for
IL-4. Following this 50ng/mL of phorbol myristate acetate
(PMA) and 0.5μg/mL of ionomycin were added for 4h in
the case of IFN-γ and TNF-α experiments or 5h for IL-4.
Priortointracellularstaining,cellsurfacestainingwitheither
CRTH2 and CD4, or CD4 antibodies alone, was performed
as described in Section 2.3. Cells were then ﬁxed with 2%
paraformaldehyde (PFA) and incubated at 37◦C for 15mins
in the dark. Cells were washed and resuspended in 0.5%
saponin and incubated for 30mins on ice in the dark to
permeabilize the cells. After incubation, cells were washed
and resuspended in 0.5% saponin for intracellular staining
with the relevant antibody; IL-4 PE/Cy7 (BioLegend, San
Diego, CA, USA), IFN-γ-(ﬂuorescein isothiocyanate (FITC)
or TNF-α-FITC (BD Biosciences, Franklin Lakes, NJ, USA).
Appropriate isotype controls were used; PE/Cy7 Rat IgG1κ
(Biolegend), or FITC Mouse IgG1κ (BD Biosciences, Oxford,
UK). Cells were incubated in the dark for 1h at room
temperatureforIL-4stainingor20minsoniceforIFN-γ and
TNF-α staining. Finally, cell suspensions were washed with
0.5% saponin and resuspended in PBS for ﬂow cytometry
analysisasfollows:ForwardscatterE0v oltage;1.00Ampgain
Lin; side scatter of 329 Voltage; 1.00 Amp gain Lin.
2.5. Flow Cytometry. Flow cytometry of lymphocytes was
carried out using FACSCalibur ﬂow cytometer (BD Bio-
sciences) equipped with FACSCalibur software for analysis.
The lymphocyte population was gated on the scatter plot
as determined by the characteristic forward scatter (FS) and
side scatter (SC) which indicates the cell size and shape. The
analysis was of CD4+,C R T H 2 +, and CRTH2+/CD4+ in the
CRTH2 expression studies and IL-4+,I L - 4 +/CRTH2+,T N F -
α+/CD4+,a n dI F N - γ+/CD4+ for the intracellular cytokines.
The expression levels of CRTH2, CD4, and intracellular
cytokineswereevaluatedbythepercentageofcellsexpressing
the protein of interest or by mean ﬂuorescence intensity
(MFI).
2.6. Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophore-
sis (SDS-PAGE) and Western Blotting. Following culture
and treatments, cells were collected using a 1mL pipette
and incubated on ice in whole cell lysis buﬀer (Cell
Signalling, Beverly, MA, USA) with 5μL/mL of protease
inhibitor (Sigma) lysis buﬀer for 5mins and centrifuged for
20mins at 13,000rpm at 4◦C. The supernatant was stored at
−80◦C until use. Prior to SDS-PAGE, protein concentrations
were determined using the BIORAD quantiﬁcation assay
measuring absorbance at 655nm. Approximately 15μgo f
extracted protein per sample was resolved by SDS-PAGE and
subsequently transferred onto polyvinyl diﬂuoride (PVDF)
membranes (GE Healthcare) 100V constant at 4◦C. Fol-
lowing transfer, the membrane was then blocked in 5%
(wt/vol) milk in tris-buﬀered saline (TBS) supplemented
with 0.1% Tween 20 (TBST) for 1h. The membrane was
then probed with phospho-p65 (Ser 536) (Cell signalling)
primary antibody (1:1000 in tris-buﬀered saline) overnight
at 4◦C followed by the appropriate secondary antibody
(1:2000 in 1% milk/TBS) for 1h at room temperature.
ChemiluminescencedetectionwasthencarriedoutwithECL
Plus (GE Healthcare), and the membranes developed using a
high-performancechemiluminescenceﬁlm(GEHealthcare).
Blots were scanned, and densitometry was performed with
ImageJ (v1.44p).
2.7. Statistical Analysis. Experimental sample groups con-
sisted of at least 4 biological replicates unless otherwise
stated. Statistical analysis was performed with Graph-Pad
Prism (v4.0; GraphPad Software, San Diego, CA, USA).
Paired Student’s t-test or repeated measures ANOVA was
conducted where appropriate. Samples with P<0.05 was
considered to be statistically signiﬁcant.
3. Results
3.1.GestationalEﬀectonTh1andTh2Cytokines. Ac hangein
the production of the Th1 and Th2 cytokines in pregnancy
has previously been described. In this study, we employed
ﬂow cytometry to examine the eﬀect of stimulation by
the mitogen PMA/ionomycin on cytokine production at
diﬀerent gestational stages of pregnancy and during labour
(see Figure 1). Th1 cytokine proﬁles of CD4 positive cells
were assessed for intracellular IFN-γ and TNF-α (Figures
1(a)–1(d)) and compared to levels of nonpregnant controls.
The percentage of peripheral T cells producing IFN-γ in
response to stimulation reduced in pregnancy from 10.7%
in nonpregnant women to 6.7% at 28 weeks, 5.1% at
term (P<0.05), and 5.6% at term in labour (P<
0.05). Similarly, the proportion of TNF-α producing cells
was reduced, although not signiﬁcantly, from 20.6% in
nonpregnant women to 14.5% at 28 weeks, 15.8% at term
and 13.3% at term in labour. Overall levels of Th1 cytokine
production(expressedasmeanﬂuorescenceintensity),inthe
CD4+/IFN-γ+ or CD4+/TNF-α+ cells remained consistent
throughout gestation and unchanged compared to nonpreg-
nant controls. The Th2 cytokine, IL-4, was similarly assessed
in CRTH2 positive cells (Figures 1(e) and 1(f)). While
PMA/ionomycin stimulation did not increase the percentage
of IL-4 expressing cells, the mean ﬂuorescence intensity of4 Mediators of Inﬂammation
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Figure 1: Th1 and Th2 cytokine production in peripheral T cells from nonpregnant and pregnant women. Peripheral blood mononuclear
cells were isolated and stimulated with PMA/ionomycin. The percentage of CD4+/IFN-γ+,C D 4 +/TNF-α+, and CRTH2+/IL-4 positive cells
were detected by ﬂow cytometry in samples derived from nonpregnant (NP), 28-week pregnant, term no labour (TNL), and term labour
(TL) samples (a), (c), and (e). A reduction in the percentage of peripheral CD4 positive cells secreting the Th1 cytokines IFN-γ and TNF-α
was observed, whereas the percentage of cells secreting the Th2 cytokine, IL-4, remained consistent throughout gestation. Mean ﬂuorescence
intensity (MFI) was also assessed as a measure of total cytokine production (b), (d), and (f). PMA/ionomycin stimulation induced both Th1
and Th2 cytokine production in all sample groups compared to NL controls. No diﬀerences in gestation-dependent responses were detected.
(g) a ratio of IFN-γ:IL-4 revealed a decrease in the Th1:Th2 ratio during pregnancy, which was increased prior to the onset of labour. For
statistical analysis ANOVA with Dunnett’s multiple comparison test with NP as a control was used; ∗∗P<0.01 and ∗P<0.05.Mediators of Inﬂammation 5
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Figure 2: CRTH2 expression in lymphocytes derived from nonpregnant and pregnant subjects. Lymphocytes were gated according to
forward scatter and side scatter and T helper cells were identiﬁed using CD4 as a cell surface marker (n = 8 for each group). A representative
cytogram from a woman of 28-week gestation is presented with the right upper quadrant showing CRTH2+/CD4+ lymphocytes (a). The
percentage of CRTH2 positive T helper cells (presented as a percentage of positive CD4 positive cells) increased slightly in the third trimester,
although statistical signiﬁcance was not reached (b). No change in mean ﬂuorescence intensity was detected in either the nonpregnant or
pregnant samples (c). For statistical analysis ANOVA with Dunnett’s multiple comparison test with NP as a control was used.
IL-4 was signiﬁcantly increased in samples collected from
women at 28 weeks (39.3, P<0.01) and at term (39.4,
P<0.05) compared to levels of nonpregnant controls (37.1).
Levels of IL-4 in term labouring samples were consistent
with nonlabouring samples (37.1). The ratio of the IFN-
γ:IL-4 producing cells reduces during pregnancy, due to the
suppression of the Th1 rather than the promotion of the Th2
cytokine production (Figure 1(g)).
3.2. CRTH2 Expression. To determine whether the Th2
response in pregnancy is reﬂected by an increase in the
percentageofCRTH2positivecells,weusedCD4asamarker
of T helper cells and calculated the percentage these cells
thatexpressCRTH2(Figure 2(a)).ThepercentageofCRTH2
positive cells in the CD4 positive population was observed to
increase in the second trimester of pregnancy from 2.24% in
nonpregnantwomento3.12%at28weeksbeforereducingto
2.75% at term and 2.4% in term labour, although statistical
signiﬁcance was not reached (Figure 2(b)). There was no
signiﬁcant increase in the mean ﬂuorescence intensity of
CRTH2 in T helper cells between nonpregnant and pregnant
subjects (Figure 2(c)), although a slight increase in CRTH2
production was noted in term labouring samples (P = 0.15).
3.3. The Eﬀect of 15dPGJ2 o nt h eT h 1a n dT h 2C y t o k i n e s .
15dPGJ2 is an anti-inﬂammatory PG and a ligand for
CRTH2. We therefore explored the eﬀect of 15dPGJ2 on
the Th1 cytokines, IFN-γ and TNF-α. To do this, cells were
preincubated with 32μMo f1 5 d P G J 2 or vehicle control
prior to the addition of PMA/ionomycin before intracellular
cytokines were detected by ﬂow cytometry (Figures 3(a) and
3(b)). 15dPGJ2 reduced the production of PMA/ionomycin
stimulated IFN-γ production (measured as mean ﬂuores-
cence intensity) in T helper cells from 101.9 to 53 (P<
0.01) in nonpregnant controls, 115.7 to 52.4 (P<0.01)
in 28 week samples and from 110 to 60.7 in term (P<
0.01) samples. There was a nonsigniﬁcant decrease observed
in term labouring samples also (88.3 to 66.3, Figure 3(c)).
Similarly, a signiﬁcant decrease in PMA/ionomycin-induced
TNF-α production following treatment with 15dPGJ2 was
detected in all pregnant samples assessed (Figure 3(d)).
The percentage of T helper cells producing IFN-γ was
also reduced from 10.7% to 5.13% in nonpregnant women6 Mediators of Inﬂammation
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Figure 3: Eﬀect of 15dPGJ2 on Th1 and Th2 cytokines. Peripheral blood mononuclear cells were incubated with vehicle control or 32μM
of 15dPGJ2 and stimulated with PMA/ionomycin before being gated on the lymphocyte population according to forward and side scatter.
A representative 28-week patient sample is presented with CD4+/IFN-γ+ cells shown in the right upper quadrant (a). A representative
histogram reveals a clear shift to the right upon stimulation indicative of increased IFN-γ producing cells (b). This eﬀect was attenuated
with 15dPGJ2 pre-treatment. PMA/ionomycin induced IFN-γ and TNF-α production was decreased with 15dPGJ2 treatment (c) and (d);
however, levels of IL-4 remained unchanged. No change in IL-4 producing cells was detected (e). For statistical analysis a Student’s t-test was
used to compare means between paired treated and nontreated samples; ∗∗P<0.01 and ∗P<0.05.Mediators of Inﬂammation 7
(P<0.01), 6.6% to 3.4% at 28 weeks (P<0.01), 5.1% to
2.5% at term (P<0.05), and 5.6% to 2.9% (P<0.01). A
reduction in the percentage of T cells producing TNF-α was
alsoseenwith15dPGJ2 from20.6%to16.7%innonpregnant
women, 14.5% to 9.0% at 28 weeks (P<0.05), 15.8% to
12.9% at term (P<0.01), and 13.2% to 8.93% at term in
labour (P = 0.05) (data not shown).
Considering its anti-inﬂammatory properties, it was
hypothesized that 15dPGJ2 would induce an increase in
IL-4 production via its action on the CRTH2 receptor.
Contrary to what was anticipated, 15dPGJ2 had no eﬀect on
the production of IL-4 (Figure 3(e)). Consistent with this,
the percentage of CRTH2+/IL-4+ lymphocytes remained
constant following 15dPGJ2 treatment except for samples
collected at 28 weeks gestation (1.65% to 1.16%, P<0.05;
data not shown).
3.4. 15dPGJ2 Inhibits PMA/Ionomycin-Stimulated NF-κB
Activation in Peripheral Blood Mononuclear Cells. Peripheral
blood mononuclear cells were incubated with vehicle control
or 32μM 15dPGJ2 and stimulated with PMA/ionomycin
for 10min before being extracted and assessed for levels of
phosphorylated p65, the transcriptionally active subunit of
NF-κB. PMA/ionomycin treatment stimulated NF-κB phos-
phorylation in all samples and at all gestational time points
(Figure 4). Pretreatment of cells with 15dPGJ2 signiﬁcantly
reduced levels of p-p65 in samples collected from women
at 28-week gestation. A clear trend of decreased p-p65
following 15dPGJ2 was observed in the remaining samples
yet they did not return to basal levels of p-p65.
4. Discussion
The immunological paradox of pregnancy relies on a careful
balance of both immune tolerance and immune suppression.
Work by Medawar, and later Wegmann and colleagues, has
led to the proposal that this balance is determined by a func-
tional immune suppression via a shift from a Th1 response
to a Th2 bias during pregnancy [10, 20, 32]. Although not
all human and murine studies support the importance or the
simpliﬁcation of the Th1:Th2 paradigm [18, 19, 33], further
understanding of this hypothesis to aid the development of
new therapeutic strategies is still required. In this study, we
have explored the Th1 cytokines IFN-γ and TNF-α,a n d
the Th2 cytokine IL-4 throughout pregnancy, and examined
the potential of the cyclopentenone PG CRTH2 agonist,
15dPGJ2, to act as a therapeutic agent to modulate the
Th1:Th2 response.
Consistent with the notion of suppressed Th1 cytokine
response throughout gestation [16, 17, 34, 35], our results
revealed a reduction in the percentage of IFN-γ and TNF-
α-secreting T helper cells during pregnancy in response
to PMA/ionomycin stimulation (Figures 1(a) and 1(c)).
However, mean production of IFN-γ and TNF-α remained
constant within the CD4+/IFN-γ+ and CD4+/TNF-α+ cell
populations (Figures 1(b) and 1(d)). This indicates that
while fewer cells maintain the capacity to initiate a Th1
response to inﬂammatory stimuli with advancing gestation,
a compensatory mechanism facilitates increased IFN-γ and
TNF-α production. These results suggest that Th1 response
duringgestationislikelytoberegulatedatbothanindividual
cellular level as well as at the level of the cell population.
As normal human labour reﬂects a proinﬂammatory
state, we anticipated that the percentage of IFN-γ and TNF-
α producing T helper cells would increase with the onset of
labour. However, no diﬀerence between term nonlabouring
and term labouring samples was detected. This may be due
to the proinﬂammatory state of labour being a localized
response in the uterus and fetal membranes, rather than
an extending to peripheral inﬂammation. This would be
consistent with the localised increase in the DNA binding
activity of NF-κB in amnion cells postlabour compared to
prelabour [36] and in myometrium during labour compared
to pre-labour [37]a sw e l la st h er e p o r t e di n c r e a s ei nl a b o u r
of IFN-γ in amnion, choriodecidua, and placenta [38], and
TNF-α in the amniotic ﬂuid, myometrium, and cervix [39,
40] rather than in the peripheral blood.
A number of studies have shown that mitogen stimula-
tion can induce IL-4 production in PBMCs of the second
and third trimesters of pregnancy in vitro [16, 35, 41].
Intrinsic IL-4 production by PBMCs also shows an increase
in pregnancy compared with nonpregnant controls [17, 42].
We therefore hypothesized that PMA/ionomycin stimulation
of PMBCs would drive IL-4 production during pregnancy,
and that this phenomenon would subside at term concurrent
with the activation of inﬂammatory pathways involved in
normal labour pathways. To examine any evidence of a
shift towards the Th2 proﬁle in peripheral blood during
pregnancy, PBMCs were gated for CRTH2 (a marker for
Th2 cells) and the level of IL-4 assessed (Figures 1(e) and
1(f)). The percentage of CRTH2+/IL-4+ secreting cells, as
well as mean production levels of IL-4 remained consistent
throughout pregnancy and advancing gestation (Figures 1(f)
and 1(e)) although a slight increase in the percentage of IL-
4 secreting cells was observed in both nonstimulated and
stimulated28-weeksamples.Between0.4–6.5%ofperipheral
blood CD4+ cells of nonpregnant women express CRTH2
and secrete IL-4, but not IFN-γ,i nr e s p o n s et oP M A
and ionomycin and are thus typical of Th2 cells [43].
Consistent with this, we found that between 2–4% of CD4+
PMBCs express CRTH2 (Figure 2(a)). This percentage was
maintained throughout gestation with a minor, statistically
nonsigniﬁcant, increase observed at 28 weeks (Figure 2(b)).
Tsuda et al. have previously reported an increase in CRTH2
expression in CD4+ cells between nonpregnant (2.08%)
and 7-week gestation (3.43%, P = 0.02) [44], but it is
possible that this eﬀect is diminished with advancing ges-
tation. Mean levels of CRTH2 expressed in CD4+ cells were
also unchanged through gestation and labour (Figure 2(c)).
Taken together with the fact that we were unable to detect
any diﬀerence in IL-4 secretion levels in these cells upon
mitogen stimulation, our results collectively suggest that the
Th2 response in PMBCs is maximised during pregnancy and
cannot be further stimulated. This would imply that any
beneﬁcial eﬀects of therapeutic agents intended to push the
Th2:Th1 ratio towards Th2 would need to do so through
inhibitionofTh1,ratherthanupregulationofTh2.Although8 Mediators of Inﬂammation
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Figure 4: The eﬀect of 15dPGJ2 on NF-κB p65 phosphorylation in peripheral blood mononuclear cells. PBMCs were treated as previously
described before being extracted and levels of phosphorylated p65 (p-p65) examined using immunoblotting. Representative immunoblots
are shown for each gestational time point (a). Immunoblots were reprobed for β-actin as an internal loading control. Densitometric analysis
of the immunoblots was conducted revealing a signiﬁcant increase in p-p65 levels upon stimulation with PMA/ionomycin in all samples (b).
A signiﬁcant decrease in PMA/ionomycin stimulated p-p65 was observed following 15dPGJ2 treatment in 28-week samples. The capacity
of 15dPGJ2 to inhibit PMA/ionomycin-induced p-p65 was lost in those samples collected at term. NS: nonstimulated, S: PMA/ionomycin
stimulated, and J2: 15dPGJ2 pretreatment. Eﬀect of treatment was examined for statistical signiﬁcance at each gestational timepoint using
ANOVA with Bonferroni’s multiple comparison test; ∗∗∗P<0.001, ∗∗P<0.01 and ∗P<0.05.
the percentage of CRTH2 expressing CD4+ cells is low in
the peripheral blood, we are unable to rule out any modest
yet biologically signiﬁcant changes in IL-4 production from
these cells at a tissue-speciﬁc level.
To further investigate the potential of Th2 promotion
versusTh1suppression,weexaminedtheresponseofPBMCs
to 15dPGJ2, an endogenous product of Prostaglandin D2
(PGD2) (and potential therapeutic agent) that has been
shown to promote Th2 bias through IL-4 production in
T helper 2 cells in vitro via CRTH2 [24]. PGD2 is readily
converted to 15dPGJ2 by a series of dehydration reactions in
the presence of albumin and is found in the amniotic ﬂuid
[45], placenta [46], and urine [47]. 15dPGJ2 pretreatment
signiﬁcantly inhibited the PMA-stimulated production of
both Th1 cytokines: IFN-γ and TNF-α, in nonpregnant
and all pregnant samples (Figures 3(a)–3(d)). However,
no eﬀect on the production of the Th2 cytokine, IL-4,
could be detected in response to 15dPGJ2 treatment. This
may be due to an overriding eﬀect of a non-CRTH2-
mediated mechanism such as the inhibition of other sig-
nalling proteins involved the transcriptional regulation of
IL-4 expression. Evidence for this has been previously
reported in a PMA/Ionomycin-activated T-cell line, where
15dPGJ2 inhibited IL-4 production in a dose-dependent
manner through the downregulation of nuclear factor of
activated T-cells (NF-AT) activation [48].
The anti-inﬂammatory properties of 15dPGJ2 are
thought to be at least partly via the inhibition of the
transcription factor NF-κB[ 49]. NF-κB is known to play a
key regulatory role in controlling the Th1 immune response
by modulating the expression of Th1 cytokines [31]. NF-κB
activity in PBMCs during pregnancy is reduced compared
to nonpregnant controls [50], and it has therefore been
suggestedthatthisisresponsibleforsuppressedTh1response
in pregnancy [30]. To determine whether the observed
inhibitory eﬀects of 15dPGJ2 on Th1 cytokine production
may be via NF-κB, treated cells were extracted, and levels
of the transcriptionally active NF-κB subunit p-p65 were
examined by immunoblotting. Our results indicate that
15dPGJ2 signiﬁcantly inhibits p-p65 in PMA/ionomycin
stimulatedThelperat28weeksofgestation.Anonsigniﬁcant
reduction was also observed in nonpregnant controls andMediators of Inﬂammation 9
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Figure 5: Schematic proposal of the Th1 and Th2 balance and the role of CRTH2 and NF-κB. T-helper cell precursors are directed toward
committed immunophenotype by the typical Th1 and Th2 interleukins, IFN-γ and IL-4, respectively. Infection or propregnancy hormones
such as progesterone can further modulate the Th1/Th2 bias. Based upon our ﬁndings and those of others, we propose that 15dPGJ2
maintains a Th2 bias principally through the suppression Th1 interleukins through the inhibition of NF-κB.
samples acquired at term. This data provides evidence that
the Th1 inhibitory properties of 15dPGJ2 are likely regulated
through NF-κB.
15dPGJ2 is a cyclopentenone PG which possesses an α,β-
unsaturated carbonyl group in the cyclopentenone ring [51].
This group can form Michael adducts with I Kappa B kinase
(IKK) [52], and the p65 [53] and p50 subunits leading to
modiﬁcation of these proteins, thus inhibition of NF-κB
activity [51]. We have shown that in amnion and myometrial
cells, inhibition of NF-κB by 15dPGJ2 is not via PPAR-γ [28].
However, 15dPGJ2-mediated suppression of Th1 interleukin
expression in lymphocytes via PPAR-γ receptor inhibition
or activator protein 1 (AP-1) has not been ruled out in this
study.
While 15dPGJ2 appears to have no eﬀect on the
peripheral Th2 response, the demonstrated inhibition of
the Th1 response represents a collective shift toward a
Th2 bias, or in other words, an increase in the Th2:Th1
ratio. This has important ramiﬁcations for the future design
of therapeutic strategies to prevent preterm labour and
pregnancyloss(Figure 5).ThepercentageofCRTH2positive
deciduallymphocytesisfarhigher,accountingfor10.5%ofT
lymphocytes and 18% of CD4+ lymphocytes [44]. Exploring
the eﬀect of 15dPGJ2 on puriﬁed decidual T cells may give
rise both Th1 suppression and Th2 cytokine promotion.
Immunomodulating therapies such as progesterone (for
women at high risk of preterm labour) and intravenous
Immunoglobulins (for women with recurrent miscarriage)
are currently being used in a clinical context. Proges-
terone suppresses IFN-γ production in peripheral blood
mononuclear blood cells cultured with trophoblasts [54]
and dydrogesterone suppresses both IFN-γ and TNF-
α whilst increasing IL-4 in phytohaemagglutinin (PHA)
stimulated PBMCs leading to a substantial Th1 to Th2
shift [55]. Immunoglobulins are capable of altering the
Th1:Th2 balance leading to a reduction in the CD4+IFN-
γ+/CD4+IL-4+ lymphocyte ratio [56]. The endogenous pro-
tein,progesterone-inducedblockingfactor(PIBF),iscapable
of increasing the production of IL-4 and IL-10 in PBMC, but
has no eﬀect on the Th1 cytokines IFN-γ and TNF-α [57].
15dPGJ2 mayshowmorepromisingimmunomodulating
eﬀects for the prevention of preterm labour exploiting
its ability to both suppress the Th1 cytokines with the
added beneﬁt of inhibiting NF-κBa c t i v i t y .P r e t e r ml a b o u r ,
particularlyinthepresenceofchorioamnionitis,isassociated
with a shift towards the Th1 cytokine response [58]. PBMCs
of women in preterm labour when stimulated with PMA
produce signiﬁcantly higher IFN-γ compared to womenwho
go on to deliver at term [59] .T h ep r e s e n c eo fI F N - γ in cer-
vicovaginal ﬂuid in the late second and early third trimesters
has also been shown to be a risk factor for preterm labour in
asymptomatic women [60]. Similarly, TNF-α is thought to
be key cytokine involved in the initial trigger of biochemical
events leading to infection-mediated preterm birth, for
example, by causing prostaglandin E2 (PGE2) synthesis by
intrauterine tissues which drive pathways leading to uterine
contractility and cervical ripening [61–63]. While global
changes in the PBMCs likely reﬂect important systemic
inﬂammatory events, their sub-components (e.g., T cells,
B cells, and monocytes) may play functionally independent10 Mediators of Inﬂammation
roles at the maternal fetal interface. Future work using an
in vivo model examining eﬀects of 15dPGJ2 and CRTH2
agonists on Th1 and Th2 interleukins at local sites (e.g.,
decidua and myometrium) would allow us to extrapolate
how immune cells inﬂuence nonimmune cell function.
Prophylactic administration of 15dPGJ2 to women at
high risk of preterm birth may lead to the inability of
infection to activate NF-κB and thus preventing transcrip-
tion of labour associated genes, and the inability to alter
the Th1:Th2 bias to favour Th1, thus preventing the pro
inﬂammatory detrimental environment of the fetus. Consid-
eration for the route of administration should be supported
by further studies of the potential local eﬀect of 15dPGJ2
on interleukin production from the cervix, myometrium,
and fetal membranes. The anti-inﬂammatory eﬀect on NF-
κB and the Th1 interleukins may not be replicated in the
cervix, for example, which would serve as the least invasive
route of administration of 15dPGJ2 in the form of a pessary.
Absorption at the local level is also unlikely to provide
systemic levels high enough to eﬀect peripheral cytokine
production, likewise, the eﬀect of peripheral administration
on the local maternal fetal interface is not guaranteed to
result in a physiological eﬀect. Nevertheless, this study shows
promising potential for the future application of 15dPGJ2
as an immunomodulating therapy for infection-mediated
preterm labour, and thus further studies examining its eﬀect
on gestational tissues should be pursued.
5. Conclusion
This study presents evidence that the Th1:Th2 balance is
changed in pregnancy through Th1 suppression rather than
Th2 promotion. We have also demonstrated the potential
anti-inﬂammatory eﬀects of 15dPGJ2 through the suppres-
sion of NF-κB and the Th1 proinﬂammatory cytokines
IFN-γ and TNF-α. These properties may be of therapeutic
beneﬁt for the prevention of infection-mediated preterm
labour and the reduction of inﬂammation induced neonatal
morbidity, where an aberrant proﬁle favouring the Th1
response is seen. Thus, future work in this area may be best
directed toward designing therapeutic strategies aimed to
manipulate the Th1 response during pregnancy as a rational
strategy for the prevention of preterm labour and pregnancy
loss/miscarriage.
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